**Technology Appraisal Committee B Interests Register**

**Topic: Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura [ID1185]**

**Publication Date: 16/12/2020**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Name | Role with NICE | Type of interest | Description of interest | Interestarose | Interestdeclared | Interest ceased | Comments |
| Dr Will Lester | Clinical Expert | Direct financial | Previously received funding for attending advisory board meetings for Sanofi | N/A | 02/09/2019 | N/A | It was agreed that this declaration would not prevent Dr Lester from participating in part 1 of the meeting.  |
| Professor Marie Scully  | Clinical Expert  | Direct financial  | Received honorarium for attending advisory board panels and speaking engagements on TTP at Sanofi meetings and congresses | N/A | 02/09/2019 | N/A | It was agreed that this declaration would not prevent Professor Scully from participating in part 1 of the meeting |
| Dr Rhiannon Owen | TAC B Committee Member | Direct financial  | Previously received consultancy fees from Roche. | N/A | 01/05/2020 | N/A  | It was agreed that this declaration would not prevent Rhiannon Owen from participating in part 1 and part 2 of this meeting.  |
| Peter Wheatley Price  | TAC B Committee Member | Direct financial | Works for Takeda who are in phase 3 of producing a potential competitor product for caplacizumab | N/A | 05/2019 | N/A | It was agreed that this declaration would prevent him from participating in this section of the meeting. |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |